Company Overview
F-star is a next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.
Modular Antibody Technology allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, small sized antibody fragments with full antibody functionality and long inherent half-life (Fcab™) or full length antibodies with dual specificity (mAb² ™) can be created.
F-star's management team has many years of experience in the biotech and pharmaceutical industry, covering antibody engineering, pharmaceutical development, intellectual property, business development and finance.
F-star enjoys strong financial support from a world-class group of life science investors including Aescap Venture, Atlas Venture, Merck-Serono, MP Healthcare, Novo A/S, SR One and TVM Capital. Founded in 2006 and based on discoveries made by Professor Florian Rüker (BOKU), the Company currently employs more than 20 highly qualified people at its research sites in Vienna, Austria and Cambridge, UK.